Integrating multi-omics technology to discover the causes and prognosis of primary central nervous system lympoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035880

Enrollment

Unknown

Registered

2020-08-19

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma (PCNSL)

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. any age and gender; 2. pathologic confirmed PCNSL, tumor tissue embedded in paraffin; or ibrutinib treated refractory/relapse PCNSL; or suspecious PCNSL, planning to do surgery or biopsy; 3. non-lymphomatic central nervous system diseases, planning to do surgery or decompression to remove the tumor/lesion with some normal tissue; 4. systemic diffuse large B cell lymphoma without central nervous system infiltration; or suspecious cases of systemic lymphoma without central nervous system infiltration, planning to do surgery/biopsy; 5. fully understanding the study with informed consent.

Exclusion criteria

Exclusion criteria: 1. undable to sustain the surgery/biopsy with severe heart/lung diseases or coagulation abnormity; 2. unqualified sample; 3. no surplus sample; 4. unwilling to provide the information, unwilling to participate in the study.

Design outcomes

Primary

Measure	Time frame
whole exome sequencing;single cell sequencing;ctDNA;MRI;	—

Secondary

Measure	Time frame
cytokinesis;Blood routine test;liver function;renal function;overall survival;progression free survival;16s RNA;	—

Countries

China

Contacts

Public ContactCHEN Tong

Huashan Hospital, Fudan University

chentong@fudan.edu.cn+86 21 52887102

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026